Presented here at the Alzheimer's Association International Conference (AAIC) 2012, a small, open-label extension phase 2 trial showed that at 36 months, IVIG slowed the rate of expected cognitive decline in all participants. But the most striking finding was that it stopped decline in a subset of patients who received what proved to be the optimal dose of the immunotherapy for the entire study period.For this subset of 4 patients, measures of cognition, memory, daily functioning, and mood were unchanged from baseline after 3 years of treatment.
No comments:
Post a Comment